Oculis Holding AG (OCS) Long-Term Investments (2021 - 2025)
Oculis Holding AG (OCS) recorded quarterly Long-Term Investments of $239.1 million in Q4 2025, up 9.61% quarter-over-quarter from $218.1 million in Q4 2024, and up 9.61% on a YoY basis from $218.1 million in Q4 2024.
Oculis Holding AG (OCS) Long-Term Investments (2021 - 2025) Analysis & Trends
Oculis Holding AG's Long-Term Investments history runs 5 years deep, the most recent figure standing at $239.1 million for Q4 2025.
- In Q4 2025, Long-Term Investments rose 9.61% year-over-year to $239.1 million; the TTM figure through Dec 2025 stood at $239.1 million (up 9.61% YoY), while the FY2025 annual figure was $239.1 million, up 9.61% from the prior year.
- Long-Term Investments was $239.1 million for Q4 2025 at Oculis Holding AG, up from $218.1 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $239.1 million in Q4 2025 to a low of $51901.1 in Q4 2022.
- Historically, Long-Term Investments has averaged $134.5 million across 5 years, with a median of $215.4 million in 2023.
- The sharpest annual moves came in 2022 and 2023: Long-Term Investments fell 7.97% in 2022, then jumped 414920.6% in 2023.
- A 5-year view of Long-Term Investments shows it stood at $56394.1 in 2021, then slipped by 7.97% to $51901.1 in 2022, then surged by 414920.6% to $215.4 million in 2023, then gained by 1.26% to $218.1 million in 2024, then rose by 9.61% to $239.1 million in 2025.
- The last three Long-Term Investments figures came in at $239.1 million (Q4 2025), $218.1 million (Q4 2024), and $215.4 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 239.06 Mn |
| Dec 31, 2024 | 218.11 Mn |
| Dec 31, 2023 | 215.40 Mn |
| Dec 31, 2022 | 51,901.10 |
| Dec 31, 2021 | 56,394.11 |